143 related articles for article (PubMed ID: 10051053)
21. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
22. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U; Ullrich S; Roskos M; Misselwitz J
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.
Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
Transplant Proc; 2006 Sep; 38(7):2132-4. PubMed ID: 16980022
[TBL] [Abstract][Full Text] [Related]
24. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
Lehmkuhl H; Ross H; Eisen H; Valantine H
Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
[TBL] [Abstract][Full Text] [Related]
25. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
26. Pretransplant test-dose pharmacokinetic profiles: cyclosporine microemulsion versus corn oil-based soft gel capsule formulation.
Chueh SC; Kahan BD
J Am Soc Nephrol; 1998 Feb; 9(2):297-304. PubMed ID: 9527407
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
28. Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients.
Joshi AS; King SY; Zajac BA; Makowka L; Sher LS; Kahan BD; Menkis AH; Stiller CR; Schaefle B; Kornhauser DM
J Clin Pharmacol; 1997 Dec; 37(12):1121-8. PubMed ID: 9506007
[TBL] [Abstract][Full Text] [Related]
29. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.
Murgia MG; Jordan S; Kahan BD
Kidney Int; 1996 Jan; 49(1):209-16. PubMed ID: 8770969
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
[TBL] [Abstract][Full Text] [Related]
31. Preclinical results of sirolimus treatment in transplant models.
Stepkowski SM
Transplant Proc; 2003 May; 35(3 Suppl):219S-226S. PubMed ID: 12742499
[TBL] [Abstract][Full Text] [Related]
32. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.
Kahan BD; Welsh M; Schoenberg L; Rutzky LP; Katz SM; Urbauer DL; Van Buren CT
Transplantation; 1996 Sep; 62(5):599-606. PubMed ID: 8830822
[TBL] [Abstract][Full Text] [Related]
33. Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients.
Lukas JC; Suárez AM; Valverde MP; Calvo MV; Lanao JM; Calvo R; Suarez E; Gil AD
J Clin Pharm Ther; 2005 Dec; 30(6):549-57. PubMed ID: 16336287
[TBL] [Abstract][Full Text] [Related]
34. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation.
Kahan BD; Welsh M; Rutzky L; Lewis R; Knight R; Katz S; Napoli K; Grevel J; Van Buren CT
Transplantation; 1992 Feb; 53(2):345-51. PubMed ID: 1738928
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients.
Rosenbaum SE; Baheti G; Trull AK; Akhlaghi F
Ther Drug Monit; 2005 Apr; 27(2):116-22. PubMed ID: 15795639
[TBL] [Abstract][Full Text] [Related]
36. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Junghanss C; Rathsack S; Wacke R; Weirich V; Vogel H; Drewelow B; Mueller S; Altmann S; Freund M; Lange S
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1061-8. PubMed ID: 22182476
[TBL] [Abstract][Full Text] [Related]
37. Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus.
Kahan BD; Benavides C; Schoenberg L; Podbielski J; Green C
Clin Nephrol; 2010 May; 73(5):344-53. PubMed ID: 20420794
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach.
Sumethkul V; Tankee P; Chalermsanyakorn P; Jirasiritham S
Transplant Proc; 2010 Dec; 42(10):4040-2. PubMed ID: 21168621
[TBL] [Abstract][Full Text] [Related]
39. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients.
Falck P; Asberg A; Byberg KT; Bremer S; Bergan S; Reubsaet JL; Midtvedt K
Transplantation; 2008 Nov; 86(10):1379-83. PubMed ID: 19034006
[TBL] [Abstract][Full Text] [Related]
40. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients.
Langer RM; Kahan BD
Transplantation; 2003 Jul; 76(2):318-23. PubMed ID: 12883185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
